08048036315
Eylea 40 mg/mL Inj UK Wholesale – Liverpool | Competitive Prices | Phoenix Exim | Trusted Exporter

1. General Information

Eylea 40 mg/mL is a prescription ophthalmic injection containing aflibercept. It belongs to the anti-VEGF (vascular endothelial growth factor) class of medicines.

It is administered directly into the vitreous of the eye by a qualified healthcare professional. It is primarily used to manage retinal diseases in which abnormal blood-vessel growth or leakage contributes to vision impairment.

2. Product Information

  • Brand: Eylea
  • Active ingredient: Aflibercept
  • Strength: 40 mg/mL
  • Dosage form: Solution for injection
  • Route: Intravitreal injection
  • Standard adult dose: 2 mg aflibercept in 0.05 mL for the indications listed in the UK SmPC
  • Drug class: Anti-VEGF biologic
  • Appearance: Clear, colourless to pale-yellow solution
  • Administration: By an appropriately trained ophthalmic healthcare professional only

Important: Eylea 40 mg/mL should not be confused with Eylea HD 114.3 mg/mL, which is a different, higher-strength formulation.

3. Uses of Eylea 40 mg/mL

According to the UK product information, Eylea 40 mg/mL is used in adults for:

  • Neovascular (wet) age-related macular degeneration (wet AMD)
  • Diabetic macular oedema (DME)
  • Visual impairment caused by macular oedema following retinal vein occlusion, including branch RVO and central RVO
  • Myopic choroidal neovascularisation (myopic CNV)

The exact approved indications can differ between countries, so local prescribing information should always be checked.

4. Benefits of Eylea

When appropriately prescribed, aflibercept can help:

  • Reduce abnormal blood-vessel leakage in the retina.
  • Reduce retinal or macular swelling associated with VEGF activity.
  • Control abnormal blood-vessel growth in certain retinal disorders.
  • Help preserve or improve vision in appropriate patients.
  • Provide an established anti-VEGF treatment option for several important retinal conditions.

Treatment response varies between patients, and continued treatment should be determined by the treating ophthalmologist based on visual and anatomical outcomes.

5. Side Effects of Eylea

Like all medicines administered by intravitreal injection, Eylea can cause adverse effects.

Potential risks include:

  • Eye pain or discomfort
  • Eye redness
  • Intraocular inflammation
  • Increased intraocular pressure
  • Visual disturbances
  • Cataract
  • Retinal tear or retinal detachment
  • Endophthalmitis (serious infection inside the eye)
  • Vitreous haemorrhage
  • Rare systemic vascular events

Intravitreal injections themselves can also be associated with complications, which is why appropriate sterile technique and post-injection monitoring are important.

6. Common Side Effects

Commonly reported reactions can include:

  • Conjunctival haemorrhage
  • Eye pain
  • Increased intraocular pressure
  • Vitreous floaters
  • Visual disturbances
  • Cataract
  • Retinal or vitreous haemorrhage
  • Eye irritation or inflammation

The actual frequency and severity depend on the patient's condition and treatment history. The official product information should be consulted for the complete adverse-reaction profile.

7. How to Use Eylea

Eylea is not a self-administered injection.

It must be administered intravitreally by a qualified healthcare professional experienced in administering intravitreal injections. Appropriate anaesthesia and aseptic technique are required.

For example, the UK SmPC specifies a 2 mg/0.05 mL dose for adult wet AMD, with the initial treatment generally involving monthly injections for three consecutive doses before subsequent intervals are determined according to the patient's response. Other indications have different dosing schedules.

Do not attempt to inject Eylea yourself or alter the prescribed injection schedule.

8. How Eylea Works

Aflibercept is a recombinant fusion protein that binds VEGF-A and related angiogenic factors.

VEGF plays an important role in abnormal blood-vessel growth and increased vascular permeability in several retinal diseases. By inhibiting VEGF activity, aflibercept helps reduce abnormal vascular leakage and pathological blood-vessel growth, which can help reduce retinal swelling and protect visual function.

9. Safety Advice

  • Use only under the supervision of an ophthalmologist.
  • Do not use in patients with known hypersensitivity to aflibercept or its excipients.
  • Eylea is contraindicated in patients with an active or suspected ocular/periocular infection.
  • It should not be administered when there is active severe intraocular inflammation.
  • Proper aseptic injection technique is essential.
  • Patients should be monitored after injection for signs of infection or other ocular complications.
  • Tell the doctor about planned or recent eye surgery.
  • Pregnancy and breastfeeding require specialist medical assessment.
  • Seek urgent ophthalmic assessment for severe eye pain, rapidly worsening vision, marked redness, light sensitivity or other significant symptoms following injection.
  • Store and handle the product according to its approved product information.

10. FAQs

Q1. What is Eylea 40 mg/mL?
Eylea 40 mg/mL is an aflibercept-containing anti-VEGF injection used for several retinal disorders.

Q2. What is the active ingredient?
The active ingredient is aflibercept.

Q3. What is Eylea used for?
It is used for conditions including wet AMD, diabetic macular oedema, macular oedema associated with retinal vein occlusion and myopic CNV, according to the relevant product approval.

Q4. How is Eylea administered?
It is administered by intravitreal injection into the eye by a trained healthcare professional.

Q5. Can I administer Eylea at home?
No. It requires specialist ophthalmic administration using appropriate sterile technique.

Q6. Does Eylea cure retinal disease permanently?
Not necessarily. It controls VEGF-related disease activity and may help preserve or improve vision, but ongoing monitoring and repeat treatment may be required.

Q7. Is Eylea 40 mg/mL the same as Eylea HD?
No. Eylea 40 mg/mL and Eylea HD 114.3 mg/mL are different formulations and strengths.

Q8. Who decides the injection schedule?
The treating ophthalmologist determines the schedule based on the patient's diagnosis and visual/anatomical response.

11. Substitutes for Eylea

Possible therapeutic alternatives in the anti-VEGF category include:

  • Ranibizumab (Lucentis)
  • Faricimab (Vabysmo)
  • Brolucizumab (Beovu)
  • Aflibercept biosimilar products, where approved and available
  • Bevacizumab (Avastin) may be used in ophthalmology in certain settings, often off-label depending on the country and indication.

These products are not automatically interchangeable with Eylea. The appropriate alternative depends on the diagnosis, regulatory approval, clinical circumstances, availability and ophthalmologist's judgment.

12. SEO & B2B Keywords

Primary Keywords

  • Eylea 40 mg/mL Injection
  • Eylea Injection supplier
  • Eylea 40 mg/mL exporter
  • Aflibercept 40 mg/mL Injection
  • Aflibercept Injection supplier
  • Aflibercept pharmaceutical exporter
  • Eylea eye injection supplier
  • Eylea 40 mg/mL wholesale supplier
  • Eylea injection distributor
  • Eylea medicine exporter from India

Long-Tail B2B Keywords

  • Buy Eylea 40 mg/mL Injection from India
  • Eylea 40 mg/mL Injection exporter from Nagpur India
  • Aflibercept 40 mg/mL Injection supplier from India
  • Eylea Injection wholesale pharmaceutical supplier India
  • Eylea 40 mg/mL medicine exporter for international markets
  • Aflibercept Injection wholesale supplier India
  • Eylea 40 mg/mL pharmaceutical distributor
  • Eylea Injection supplier for USA and UK
  • Eylea Injection exporter to Australia and Singapore
  • Eylea Injection supplier for Canada and South Korea
  • Eylea Injection pharmaceutical supplier UAE
  • Eylea 40 mg/mL B2B medicine supplier
  • Aflibercept ophthalmic injection exporter India
  • Eylea retinal disease injection supplier
  • Eylea anti-VEGF injection supplier India

Phoenix Exim SEO Keywords

  • Phoenix Exim Eylea 40 mg/mL supplier
  • Phoenix Exim Aflibercept Injection exporter
  • Phoenix Exim pharmaceutical exporter Nagpur India
  • Eylea 40 mg/mL exporter from Nagpur
  • Aflibercept Injection exporter from Nagpur India
  • Trusted pharmaceutical exporter India
  • International medicine supplier from India
  • Eylea medicine supplier for USA UK Australia
  • Eylea pharmaceutical exporter to Canada UAE Singapore
  • Aflibercept Injection supplier for South Korea
Aug 12th, 2026 3:35 PM

Keywords